This Article Full Text Full Text (PDF) An erratum has been published Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Alert me to new issues of the journal Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Search for Related Content Social Bookmarking                            What's this?

Proposed Restructuring of NCI Clinical Trials System Calls for Increased Role of Community Oncologists: An Interview With James H. Doroshow, MD

James H. Doroshow, MD

In June 2005, after a year of development, the National Cancer Institute's (NCI's) National Cancer Advisory Board accepted a plan to restructure the NCI clinical trials system. The plan was developed by the Clinical Trials Working Group (CTWG) under the leadership of James H. Doroshow, MD, director of NCI's Division of Cancer Treatment and Diagnostics. The broad-based group includes representatives from industry; professional associations, including ASCO; and institutions involved in clinical research.

NCI's director, Andrew von Eschenbach, MD, asked Doroshow to review how clinical trials are supported across the institute, "with the notion that we need . . . [Click for More]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?